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Coordinator: Welcome and thank you for standing by. At this time all participants are in a 
listen-only mode. 
 
 During our Q&A session, you may press star 1 on your touchtone phone if 
you would like to ask a question. 
 
 Today's conference is being recorded. If you have any objections, you may 
disconnect at this time. 
 
 Now I'd like to turn the meeting over to Dr. (Raymond Strikas ). Sir, you may 
begin. 
 
(Raymond Strikas): Thank you very much and welcome to Current Issues and Immunization 
Net Conferences, a program presented by the Immunization Services Division 
of the National Center for Immunization and Respiratory Diseases at the 
Centers for Disease Control and Prevention, or the CDC, in Atlanta, Georgia. 
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 To participate in today's program, you need both a telephone connection and a 
separate Internet connection, as designated on our website for this net 
conference. 
 
 The learning objectives for today's program are: that you'll be able at the end 
of the program to describe an emerging immunization issue, in this case about 
pneumococcal disease and vaccines; to list the recent immunization 
recommendation made by the Advisory Committee on Immunization 
Practices, also called the ACIP; to be able to locate resources relevant to 
current immunization practice; and to obtain, assess and apply patient 
information to determine the need for immunization. 
 
 Today's agenda has one topic: pneumococcal disease and vaccines, which is 
part of the Epidemiology of Prevention of Vaccine-Preventable Diseases 
webinar series from our book of the same name, also called the pink book. 
The presenter will be Dr. (Andrew Kroger), who's a medical officer in our 
program at the Immunization Services Division, NCIRD, CDC. 
 
 Please make a note, if you have technical difficulty, you may dial star 0 to 
reach the operator, and when we reach the question-and-answer session, 
during that period, you can dial star 1 to get in a queue to ask questions. 
 
 Continuing education credit is available only through the CDC ATSDR 
training and continuing education online system at 
http://www2a.cdc.gov/tceonline. The continuing education credit expires on 
September 28, 2015, approximately one month from now. And when 
obtaining the continuing education, you'll be required to provide a verification 
code. Please watch and listen for this code during the course. The codes will 
not be given outside of this presentation. 
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 CDC, our planners, and our presenters wish to disclose we have no financial 
interests or other relationships with the manufacturers of commercial 
products, suppliers of commercial services, or commercial supporters. The 
presentations we give, including today's presentation, will not include any 
discussion of the unlabeled use of a product or a product under investigational 
use, with the exception of Dr. (Kroger)'s discussion of the use of 
pneumococcal vaccine in a manner recommended by the Advisory Committee 
on Immunization Practices but not approved by the Food and Drug 
Administration. CDC does accept any commercial support. 
 
 Let me turn it now over to Dr. (Kroger). 
 
(Andrew Kroger): Thank you, Dr. (Strikas). It gives me pleasure to present to you today from 
Atlanta. Today I will discuss pneumococcal disease and pneumococcal 
vaccines. 
 
 The flow of my presentation will correspond to the chapter entitled 
Pneumococcal Disease on Page 279 of the pink book. The slides that I'm 
using are similar to the sidebars you see in the margins of the pink book, and I 
will be posting these slides in the near future. 
 
 Streptococcus pneumoniae, or pneumococcus, causes an acute bacterial 
infection. This bacterium was first isolated by Pasteur in 1881 from the saliva 
of a patient with rabies. The association between the pneumococcus bacterium 
and lobar pneumonia was first described by Friedlander and Talamone in 
1883, but pneumococcal pneumonia was confused with other types of 
pneumonia until the discovery of the Gram stain in 1884. 
 
 From 1915 to 1945 the chemical structure and antigenicity of the 
pneumococcal capsular polysaccharide, its association with virulence, and the 
NWX-DISEASE CONTROL & PREVENTI (US)  
Moderator: Dale Babcock 
08-26-15/11:00 am CT  
Confirmation #4537647 
Page 4 
role of bacterial polysaccharides in human disease were explained. More than 
80 serotypes of pneumococci had been described by 1940. 
 
 Efforts to develop effective pneumococcal vaccines began as early as 1911. 
However, with the advent of penicillin in the 1940s, interest in the vaccine 
declined until it was observed that many patients still died despite antibiotic 
treatment. 
 
 By the late 1960s, efforts were again being made to develop a polyvalent 
pneumococcal vaccine. The first pneumococcal vaccine was licensed in the 
United States in 1977. The first conjugate pneumococcal vaccine was licensed 
in 2000. 
 
 Streptococcus pneumoniae bacteria are lancet-shaped Gram positive 
facultative anaerobic organisms. They are typically observed in pairs, known 
as diplococci, but may also occur singularly or in short chains. There are 92 
known serotypes. Some pneumococci are encapsulated, their surfaces 
composed of complex polysaccharides. Encapsulated organisms are 
pathogenic for humans and experimental animals, whereas organisms without 
capsular polysaccharides are not. 
 
 Capsular polysaccharides are the primary basis for the pathogenicity of the 
organism. They are antigenic and form the basis for classifying pneumococci 
by serotypes. Type-specific antibody to capsular polysaccharide is protective. 
These antibodies and complement interacts to opsonize pneumococci, which 
facilitates phagocytosis and clearance of the organism. 
 
 Antibodies to some pneumococcal encapsular polysaccharides may cross-
react with related types as well with other bacteria, providing protection 
against additional serotypes. 
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 Most Streptococcus pneumoniae serotypes have been shown to cause serious 
disease, but only a few serotypes produce the majority of pneumococcal 
infections. The ten most common serotypes are estimated to account for about 
62% of invasive disease worldwide. The ranking in serotype prevalence differ 
by patient age group and geographic area. 
 
 In the United States, prior to widespread use of the seven-valent 
pneumococcal conjugate vaccine, the seven most common serotypes isolated 
from blood or cerebral spinal fluid, or CSF, of children younger than six year 
of age, accounted for 80% of infections. These seven serotypes account for 
only about 50% of isolates from older children and adults. 
 
 Pneumococcal disease is the second most common cause of vaccine-
preventable death in the US, causing over 5,000 preventable deaths every 
year. Pneumococcal pneumonia is the most common clinical presentation of 
pneumococcal disease among adults, although pneumonia alone is not 
considered to be invasive disease. 
 
 The incubation period of pneumococcal pneumonia is short, about one to three 
days. Symptoms generally include an abrupt onset of fever and chills or 
rigors. Typically there's a single rigor, and repeated shaking chills are 
uncommon. Other common symptoms include pleuritic chest pain, cough 
productive of mucopurulent rusty sputum, dyspnea, which is shortness of 
breath, tachypnea, which is rapid breathing, hypoxia, which is poor 
oxygenation, tachycardia, which is a rapid heart rate, malaise and weakness. 
Nausea, vomiting and headache occur less frequently. 
 
 Other clinical symptoms include the two most common forms of invasive 
disease: bacteremia and meningitis. Bacteremia is bloodstream infection, and 
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meningitis is infection of the meninges, the lining covering the brain. The 
clinical symptoms, CSF profile, and neurologic complications of 
pneumococcal meningitis are similar to other forms of purulent bacterial 
meningitis. Symptoms may include headache, lethargy, vomiting, irritability, 
fever, nuchal rigidity, cranial nerve signs, seizures, and coma. 
 
 Approximately 400,000 hospitalizations from pneumonia occur every year in 
the US. The case fatality rate is 5 to 7% and may be much higher in elderly 
persons. Current use of the PCV13 vaccine is thought to prevent 12,000 cases 
of pneumonia. 
 
 More than 30,000 cases of invasive pneumococcal disease occur each year, of 
which most are bacteremia. It occurs in as many 25 to 30% of patients that 
have pneumococcal pneumonia. The overall case fatality rate for bacteremia is 
about 15% but may be as high as 60% among elderly patients. Patients with 
asplenia, who develop bacteremia, may experience a fulminant clinical course. 
Most of the deaths prevented with current use of the vaccine occur in children. 
 
 Pneumococci cause 50% of all cases of bacterial meningitis in the United 
States. An estimated 3,000 to 6,000 cases of pneumococcal meningitis occur 
each year. One-fourth of the patients with pneumococcal meningitis also have 
pneumonia. The case rate fatality of pneumococcal meningitis is about 8% in 
children and 22% in adults. Neurologic sequelae are common among 
survivors. Persons with a cochlear implant appear to be at increased risk of 
pneumococcal meningitis. 
 
 Risk factors for invasive pneumococcal disease include age. Among children, 
70% of invasive pneumococcal disease occur in children two years old or 
younger. Invasive disease is also common in older individuals, especially 
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persons 65 years of age and older, as well as younger adults. Only 15% of 
invasive disease occurs in children younger than six years of age. 
 
 Underlying medical conditions that increase the risk of invasive 
pneumococcal disease include chronic heart disease, pulmonary disease, 
including asthma in persons 19 years old and older, liver disease, CSF leaks, 
or renal disease. Other risks include smoking cigarettes in persons 19 years 
old or older, and cochlear implants. 
 
 Other conditions that increase the risk for invasive pneumococcal disease 
include decreased immune function, especially HIV infection. Children with 
HIV infection have rates of invasive pneumococcal disease 50 times higher 
than rates among children without HIV infection. Children with asplenia are 
also at higher risk of invasive pneumococcal disease. 
 
 We do use this term functional or anatomic asplenia with intent. Functional 
asplenia includes persons with sickle-cell disease because their disease 
destroys the spleen and prevents it from functioning. The spleen is an 
important organ for preventing infection with encapsulated bacteria like 
pneumococcus. 
 
 Anatomic asplenia, by the way, means the complete absence of a spleen, 
which can occur through elective surgery for various conditions, such as non-
Hodkgin's lymphoma, or it can occur through emergent removal of the spleen, 
for instance, following trauma. 
 
 Here's a breakdown of the burden of pneumococcal disease in children. 
Bacteremia without a known site of infection is the most common invasive 
clinical presentation of pneumococcal infection among children two years of 
age and younger, accounting for 13,000 cases. Bacteremia that occurs with 
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pneumonia accounts for about 3,300 of these cases, or 12 to 16% of invasive 
pneumococcal disease among children two years of age and younger. 
 
 If you look at children five years of age and younger, there are actually a total 
of 17,000 cases of invasive pneumococcal disease, which include 700 cases of 
meningitis. With the decline of invasive Hib disease, Strep pneumoniae has 
become the leading cause of bacterial meningitis among children younger than 
five years of age in the United States. 
 
 Before routine use of pneumococcal conjugate vaccine, children younger than 
one year had the highest rates of pneumococcal meningitis, approximately 10 
cases per 100,000 population. An estimated 200 children died every year as a 
result of invasive pneumococcal disease. Although not considered invasive 
disease, an estimated five million cases of acute otitis media occurred each 
year among children younger than five years of age. And pneumococci are a 
common cause of acute otitis media detected in 28 to 55% of middle ear 
aspirates. 
 
 By age 12 months, more than 60% of children have had at least one episode of 
acute otitis media. Middle ear infections are the most frequent reason for 
pediatric office visits in the United States, resulting in more than 20 million 
visits annually. And complications of pneumococcal otitis media may include 
mastoiditis and meningitis. 
 
 Risk factors for invasive pneumococcal disease among children are similar to 
risk factors generally, including functional or anatomic asplenia, especially 
sickle-cell disease, and immune compromise and I've already mentioned the 
impact of HIV in children in invasive pneumococcal disease. 
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 Attendance at a child care center has also been shown to increase the risk of 
invasive pneumococcal disease and acute otitis media. Rates are also 
increased among children of certain racial and ethnic groups, including Alaska 
natives, certain American Indians, specifically Navajo and White Mountain 
Apache tribes, and African Americans. 
 
 The reason for this increased risk by race and ethnicity is not known with 
certainty, but was also noted for invasive Haemophilus influenzae infection, 
which is also an encapsulated bacterium. Children with a cochlear implant are 
at increased risk for pneumococcal meningitis, as well as patients with CSF 
leaks. 
 
 The reservoir for pneumococcal disease are human carriers. Pneumococci are 
common inhabitants of the respiratory tract and may be isolated from the nasal 
pharynx of 5 to 90% of healthy adults. Rates of asymptomatic carriage vary 
with age, environment, and the presence of upper respiratory infections. Only 
5 to 10% of adults without children are carriers. 
 
 On military installations, as many as 50 to 60% of service personnel may be 
carriers. The duration of carriage varies and is generally longer in children 
than adults. In addition, the relationship of carriage to the development of 
natural immunity is poorly understood. 
 
 Transmission of Streptococcus pneumoniae occurs as a result of direct person-
to-person contact via respiratory droplets and by autoinoculation in persons 
carrying the bacteria in their upper respiratory tract. Pneumococcal infections 
are more common during the winter and in early spring when respiratory 
diseases are more prevalent. 
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 The period of communicability for pneumococcal disease is unknown but 
presumably transmission can occur as long as the organism appears in 
respiratory secretions. 
 
 This graph of invasive pneumococcal disease rates by age group demonstrate 
that the highest rates of invasive disease occur in those younger than two 
years of age and those 65 years of age and older. These data are generated by 
CDC's active bacterial core surveillance system, or ABC's data. 
 
 ABC's data also suggests that the use of pneumococcal conjugate vaccine has 
had a major impact on the incidents of invasive disease among young 
children. The overall incidents of invasive disease among children younger 
than five years of age decreased from approximately 99 cases per 100,000 
population during 1998 to 1999 to 21 cases per 100,000 population in 2008. 
 
 The incidents of invasive disease caused by PCV7 serotypes decreased from 
82 cases per 100,000 population to 0.2 cases per 100,000 population. The 
incidents of invasive disease caused by PCV7 serotypes plus serotype 6A, a 
serotype against which PCV7 provides some cross protection, has been 
reduced by 99%. The decreases have been offset partially by increases in 
invasive disease caused by serotypes not included in PCV7, in particular 19A. 
 
 So I'm now going to talk about the pneumococcal vaccines. These vaccines 
are composed of pneumococcal polysaccharide, and the first vaccines licensed 
were considered pure polysaccharide vaccines. The first contained 
polysaccharide from 14 different types of pneumococcus and was licensed in 
1977. 
 
 In 1983 a 23-valent polysaccharide vaccine was licensed and replaced the 14-
valent form. In 2000, the first pneumococcal conjugate vaccine was licensed, 
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consisting of polysaccharide from seven types of pneumococcus conjugated to 
a protein. And in 2010, an expanded 13-valent conjugate vaccine replaced the 
seven serotype conjugate vaccine. 
 
 PPSV23 vaccine contains polysaccharide antigens from 23 types. These types 
cause 60 to 76% of invasive disease generally. However, this vaccine is not 
effective in children younger than two years of age because it does not 
generate lasting immune memory. It also has not been demonstrated to 
provide protection against pneumococcal pneumonia. For this reason, 
providers should avoid referring to PPSV23 as a pneumonia vaccine. 
 
 The pneumococcal conjugate vaccine, or PCV13, contains the original 
serotypes from PCV7, and those were 4, 9V, 14, 19F, 23F, 18C, and 6B, as 
well as the six additional serotypes: 1, 3, 5, 6A, 7F, and 19A conjugated to a 
nontoxic diphtheria cross-reactive material 197 carrier protein. It does contain 
one additional serotype that is not in PPSV23, and that's type 6A. 
 
 More importantly because it is a conjugate vaccine, it generates a long-lasting 
immune response that is useful in children as well as adults. It was approved 
by the FDA based on a demonstration of immunologic non-inferiority to 
PCV7 rather than clinical efficacy. 
 
 Between 1998 and 2009, PCV7 reduced rates of PCV7 type invasive disease 
along with serotype A by 99%, and reduced rates of invasive disease caused 
by all serotypes by 76%. 
 
 In 2008, 61% of invasive pneumococcal disease cases among children 
younger than five years of age were attributable to the serotype in PCV13. But 
those types contained in PCV7 only accounted for 2% of the cases. The 
NWX-DISEASE CONTROL & PREVENTI (US)  
Moderator: Dale Babcock 
08-26-15/11:00 am CT  
Confirmation #4537647 
Page 12 
remainder were accounted for by the additional six serotypes in PCV13, and 
serotype 19A accounted for 43% of those cases. 
 
 In 2013, 20 to 25% of invasive pneumococcal disease cases among adults 65 
years age and older were attributable to PCV13 serotypes. PCV13 serotypes 
accounted for 10% of community-acquired pneumonia cases in adults. This 
does include pneumonias with no bacteremia. The manufacturer of PCV13, 
Pfizer, was able to determine type-specific non-bacteremic pneumonia cases 
as well with the use of a urinary antigen test based on an 
immunochromatographic membrane technique. 
 
 So by knowing the frequency of serotype for various types of diseases, we can 
estimate the number of cases potentially preventable by using the vaccine in 
adults 65 years of age or older. This is going to decrease over time because 
PCV13 vaccine is preventing adult cases as it's used in children as well 
because it prevents the acquisition of carriage. 
 
 In the year 2015 the community immunity will account for 20% of the effect, 
but by 2019 it will account for 86% of the effect, the “effects” being the 
number cases preventable in adults so the direct effect of the vaccine will be 
less because of these effects of herd immunity and community immunity. 
 
 But still if you look at the right-hand column, vaccination with PCV13 in 
adults by the year 2019 will prevent 80 cases of invasive pneumococcal 
disease, 1,070 cases of inpatient community-acquired pneumonia, or CAP, 
and 1,560 cases of outpatient community-acquired pneumonia in adults 65 
years of age or older. 
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 So understanding this reduction in disease, it makes more sense if you know 
how immunogenic and effective each vaccine is. So now I'll discuss 
immunogenicity and effectiveness beginning with PPSV23 vaccine. 
 
 So while 80% of healthy adults who receive PPSV23 vaccine do develop the 
antibodies against serotypes contained in the vaccine, most estimates of 
effectiveness range between 60 to 70% against invasive disease. And this is 
among immunocompetent persons, older person and adults with underlying 
illnesses. 
 
 Effectiveness among the immunocompromised, or very old persons, is not 
demonstrated, and some effectiveness estimates are as low as 10%. And as 
I've mentioned previously, this vaccine is not thought to prevent 
pneumococcal pneumonia at all. 
 
 Pneumococcal conjugate vaccine is highly immunogenic in infants and young 
children, including those with high risk medical conditions. The efficacy of 
PCV7 was 97% effective for prevention of invasive disease caused by vaccine 
serotypes. Furthermore, children who received PCV7 had 7% fewer episodes 
of acute otitis media and underwent 20% fewer tympanectomy tube 
placements than did unvaccinated children. 
 
 PCV13 was licensed in the United States based upon studies that compared 
the serologic response of children who received PCV13 to those who received 
PCV7. These studies showed that PCV13 induced levels of antibodies that 
were comparable to those induced PCV7 and shown to be protective against 
invasive disease. 
 
 In another study of PCV13, children 7 through 11 months, 12 through 23 
months, and 24 through 71 months of age who had not received 
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pneumococcal conjugate vaccine doses previously were administered one, 
two, or three doses of PCV13 according to age-appropriate immunization 
schedules. These schedules resulted in antibody responses to each of the 13 
serotypes that were comparable to those achieved after the three-dose infant 
PCV13 series in the US immunogenicity trial, except for serotype 1, for which 
IgG GMC was lower among children age 24 to 71 months. 
 
 A randomized placebo-controlled trial, known as the CAPiTA trial, was 
conducted in the Netherlands among approximately 85,000 adults 65 years old 
or older during 2008 through 2013 to evaluate the clinical benefit of PCV13 in 
the prevention of pneumococcal pneumonia. PCV13 demonstrated 75% 
efficacy against vaccine-type invasive pneumococcal disease, and 45% 
efficacy against PCV13 serotype non-bacteremic pneumonia. 
 
 So I will now discuss recommendations for the use of these two 
pneumococcal vaccines. The PCV13 recommendations as well as the PPSV23 
recommendations for infants and children were published in MMWR on 
December 10, 2010. 
 
 A note on the complexity of recommendations for PCV13. PCV13 is 
approved by the Food and Drug Administration for children six weeks 
through 17 years of age, and for adults 50 years of age and older. But ACIP's 
recommendations and CDC's guidance do not match the package insert. 
 
 Beyond routine infant toddler recommendations, which I'm going to discuss 
shortly, ACIP recommended use of PCV13 for immunocompromised persons 
six years of age and older in 2012 and 2013, and ACIP recommended use of 
PCV13 for adults 65 years of age and older. 
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 But the routine universal recommendation for PCV13 use in children go back 
to 2010 and match to some degree the original recommendations for PCV7 
with a few important differences. 
 
 The routine recommendations for PCV13, as mentioned, are the same as 
PCV7 for children two months through 59 months of age. The vaccine should 
be administered as a four-dose series at two months, four months, six months, 
and 12 to 15 months of age. Fewer doses are needed to complete the series if 
the series is started at seven months of age or older. 
 
 The number of doses depends on the child's current age and the age at which 
the first dose was given. Children who have received one or more doses of 
PCV7 can have those doses count but they should complete the immunization 
series with PCV13. 
 
 Here is the routine catch up schedule for unvaccinated older children. These 
are children who begin the series with PCV13 but they begin the series late. If 
the age of the first dose is between 7 and 11 months of age, a primary series of 
two doses should be administered, with four weeks in between, followed by a 
booster dose after 12 months of age, and it has to be eight weeks later 
minimum. 
 
 If the PCV13 series is begun at 12 to 23 months of age, then two doses are 
recommended, separated by eight weeks. If the series is begun between 24 and 
59 months of age and the child is considered healthy, then only one dose of 
vaccine is necessary. However, if the child has an underlying medical 
condition and begins the series between 24 and 71 months of age, then two 
doses are recommended, with eight weeks between the doses. 
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 There are also recommendations for catch up in children who have received 
the complete series of PCV7. A single supplemental dose of PCV13 is 
recommended for all children 14 through 59 months of age who have received 
four doses of PCV7 or another age-appropriate complete PCV7 schedule. For 
children who have an underlying medical condition, a single supplemental 
PCV13 dose is recommended through 71 months. This includes children who 
have received PPSV23 previously. 
 
 PCV13 should be administered at least eight weeks after the most recent dose 
of PCV7 or PPSV23. This will constitute the final dose of PCV for these 
children. Now by December of 2015, this recommendation will be obsolete 
for healthy children, because on this date it will not be possible to have 
received a complete four-dose series consisting of PCV7. By December of 
2016, this recommendation also will be obsolete for the high risk children 
who have it pushed out a little bit later. 
 
 There are also recommendations for children who have received less than a 
three-dose series of PCV13 and it is - using PCV7 for instance, and it is 
slightly different from the catch up schedule in lapsed children who began the 
series with PCV13. So children age 24 to 71 months with underlying medical 
conditions who receive fewer than three doses of PCV7 should receive two 
doses of PCV13 eight weeks apart. 
 
 Children age 24 to 71 months with underlying conditions who receive any 
incomplete schedule of three doses of PCV7 before age 24 months should 
receive one dose of PCV13. 
 
 A single dose of PCV13 should be administered for children six through 18 
years of age who have not received PCV13 previously and are at increased 
risk for invasive pneumococcal disease because of anatomic or functional 
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asplenia, which includes sickle-cell disease, immunocompromising 
conditions, such as HIV infection, cochlear implant, or CSF leak. And this is 
regardless of their previous history of PCV7 or PPSV23. 
 
 Now this is the list of high risk conditions for children from the 2010 ACIP 
pneumococcal vaccine recommendations for children. Note this list includes 
both immunocompetent and immunocompromising conditions. The conditions 
listed on this slide are those that should be considered when you're playing 
catch up with PCV13 vaccine in the older infants and toddlers to determine 
whether catch up doses are needed out to 71 months as opposed to 59 months 
of age. 
 
 So notice this list includes the immunocompromising conditions like asplenia 
and other immunocompromising conditions, renal failure, which is a list that's 
important for that dose between six and 18 years. But when you're playing 
catch up in the infants and toddlers, you also want to include the chronic 
diseases like chronic heart disease, chronic lung disease, and diabetes 
mellitus. So that's why I show you this chart now. 
 
 So now I'd like to discuss PCV13 use in adults. PCV13 was licensed for use 
among adults 50 years old or older on December 30, 2011. FDA approved this 
use under an accelerated approval pathway, and it was based on serologic 
studies that compared the response of PCV13 recipients to a response of 
PPSV23 recipients. 
 
 One of the post-approval conditions of licensure was the performance of a 
randomized control trial of PCV13 against pneumococcal pneumonia among 
adults 65 years old and older in the Netherlands, which was the CAPiTA trial. 
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 Now I want to show you some data. This is the incidents of invasive 
pneumococcal disease, or IPD, in adults ages 18 through 64 years, who are 
healthy compared to those with selected underlying conditions. Cases of IPD 
per 100,000 persons are shown on the vertical axis, and various conditions are 
listed on the horizontal axis. 
 
 The two columns on the right demonstrate that individuals with hematologic 
cancer and HIV/AIDS, have a more than twenty-fold increased rate of IPS 
compared to persons without these conditions. Adults with the other 
conditions on the graph have a three to sevenfold increased risk for IPD 
compared to persons without these conditions. 
 
 So adults with immunocompromising conditions are at much greater risk of 
invasive pneumococcal disease than adults without these conditions. At the 
June 2012 ACIP meeting, the committee concluded that the benefits of 
vaccination likely outweigh any risk for use of PCV13 in 
immunocompromised adults for the entire age range of adults 19 years of age 
and older. 
 
 ACIP believes the indirect effect of PCV13 use in children are not likely to 
eliminate invasive pneumococcal disease due to PCV13 serotypes in adults. 
And so PCV13 use alone may not provide adequate coverage of the serotypes 
causing disease among the adults. Combined use of PCV13 and PPSV23 
vaccine in adults would likely be more effective than either vaccine alone. 
 
 So all of these factors kind of came into play when we were discussing 
whether to lower that age range for the immunocompromised adults from 50 
years as per licensure down to 19 years of age. And in fact, that's what we did. 
In 2012, CDC published guidance based on these ACIP recommendations that 
definitely differ from FDA's package insert. So instead, CDC recommends 
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PCV13 for the adults older than 19 years but with the certain high risk 
conditions. 
 
 And this chart lists with checkmarks the various conditions for which PCV13 
is recommended for adults. Only pay attention to the middle column with the 
header PCV13. So out of all the conditions that we've discussed in the first 
block, immunocompetent persons, only CSF leaks and cochlear implants are 
risk factors for PCV13 use in this 19 and older group of adults. But we also 
recommend PCV13 for adults with functional and anatomic asplenia. 
 
 And all of the other immunocompromising conditions are listed in the bottom 
half of the table, and I will repeat myself a little bit but repetition is good. 
Note that chronic renal failure is listed under the categorical group 
immunocompromised persons. 
 
 So adults 19 years of age and older with one of these risk factors should 
receive a dose of PCV13. Note that if that both PCV13 and PPSV23 are 
recommended, a dose of PCV13 should be administered first, followed by a 
dose of PPSV23 at least eight weeks later. I'm going to get to this a bit later in 
some more detail, but adults with one of these conditions will then be 
recommended for a second dose of PPSV23 five years later. 
 
 ACIP now as of 2014 also recommends a dose of PCV13 for all adults 65 
years of age and older. And the recommendation is for those adults that are 
PCV13 naïve, and note that some adults may have already received PCV13 
already which will lead to complexity, which I will address later. 
 
 But first let me talk about the individual recommendations for PPSV23 use in 
children and adults. So we recommend pneumococcal polysaccharide vaccine 
for persons two years old and older that have normal immune systems but 
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with the following chronic illnesses: cardiovascular or pulmonary disease, and 
for pulmonary it's asthma if it's someone 19 years of age or older, diabetes, 
liver disease, alcoholism, cigarette smokers 19 years of age and older, and 
patients with CSF leak or cochlear implants. 
 
 Pneumococcal polysaccharide vaccine should also be considered for persons 
in environments or settings with increased risk for pneumococcal disease or 
its complications, such as current Alaska native or American Indian 
populations. And of course pneumococcal polysaccharide vaccine is also 
recommended for persons two years old and older who are 
immunocompromised either due to disease or treatment. 
 
 Immunocompromising conditions, including functional or anatomic asplenia, 
chronic renal failure, nephrotic syndrome, Hodgkin's disease, lymphoma and 
leukemia, multiple myeloma, organ transplant, and HIV infection, or really 
any condition that is considered immunocompromising, and this can be a 
complicated set of conditions, especially when you consider the medications. 
 
 Routine revaccination with PPSV23 vaccine is not recommended for patients 
with those - that first set of high risk conditions grouped under 
immunocompetent persons nor is it recommended for persons with CSF leak 
and cochlear implant. 
 
 However, revaccination is recommended for persons two through 64 years of 
age who are at the highest risk of serious pneumococcal infection. And so by 
revaccination, we mean at a five-year interval, no shorter than that, between 
your two doses of PPSV23. So this is recommended for patients with 
functional or anatomic asplenia, including sickle cell disease, 
immunosuppression, including HIV infection, transplant, chronic renal failure, 
and nephrotic syndrome. 
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 Once someone turns 65 years of age, another dose of PPSV23 is 
recommended regardless of the number of previous doses of PPSV23 that had 
been given previously, but only one dose is recommended after the 65th 
birthday. 
 
 Note that because we always recommend the dose after the 65th birthday, 
patients with chronic conditions who are immunocompetent, who may receive 
a dose of vaccine in childhood or young adulthood, actually will receive a 
revaccination dose. It's just going to wait until the 65th birthday. And so I've 
listed those conditions again. 
 
 And to repeat: chronic heart disease, chronic lung disease, which includes 
asthma in persons 19 through 64 years of age, diabetes mellitus, chronic liver 
disease, CSF leak, cochlear implant, alcoholism, and cigarette smoking in 
persons 19 through 64 years of age. Again, remember a dose is recommended 
after the 65th birthday, but only one dose is recommended after the 65th 
birthday. 
 
 So now that I have discussed vaccine recommendations for PCV13 and 
PPSV23, I'd like to discuss how to use the two vaccines together. And 
remember these recommendations call on our CDC guidance, not FDA 
licensure. First, some general rules. PCV13 and PPSV23 should not be 
administered during the same clinic visit. 
 
 Either vaccine may be administered simultaneously with influenza vaccine 
and most other routinely recommended vaccines, but do not give PCV13 and 
PPSV23 together. And administer PCV13 before PPSV23. In children, this 
will generally mean finishing the series of PCV13 and then waiting eight 
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weeks, and then administering PPSV23, either one or two doses, depending on 
the risk condition. 
 
 So it's more straightforward in children, but vaccination of adults is more 
complicated. And I would now like to explain the adult recommendations as 
they've evolved over the time period 2010 to 2014. 
 
 So in 2010, all adult vaccine recommendations really involved only PPSV23 
vaccine. If an adult was immunocompetent with one of the underlying 
conditions, they would be recommended for PPSV23. And then the next dose 
would not be recommended until the 65th birthday. You would have to keep 
in mind a minimum interval that's important here. 
 
 It's a five-year interval between the two doses of PPSV23, and that's because 
this vaccine frequently causes mild local reactions upon revaccination that are 
best avoided by maintaining a five-year interval between the doses. If an adult 
had asplenia, renal disease or an immunocompromising condition, two doses 
with a minimum five-year interval should be administered prior to the 65th 
birthday, and then an additional dose after the 65th birthday. 
 
 And of course with that five-year minimum interval as well. If an adult began 
at 65 years of age and older, only one dose of PPSV23 is recommended. And 
that's everybody, immunocompetent and immunocompromised. 
 
 In 2012 came the first set of recommendations for PCV13 and adults 19 years 
old or older with immunocompromising conditions. And the risk groups 
include asplenia, renal disease, other immunocompromising conditions, and 
CSF leak and cochlear implants. So a dose of PCV13 is recommended first, 
followed by a dose of PPSV23 with a minimum interval of eight weeks. And 
we have an eight-week minimum interval. This exists to reduce the risk of 
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mild local reactions when doses of two different pneumococcal vaccines are 
administered close together in time. 
 
 After the dose of PPSV23, remember for this group a second dose of PPSV23 
is recommended five years later but only for asplenia, renal disease and 
immunocompromising conditions, not CSF leak or cochlear implants. And 
then of course a dose of PPSV23 is recommended for all after the 65th 
birthday. 
 
 Looking at the same group of individuals, what happens is PPSV23 had 
already been administered. Data show that the optimal response from PCV13 
vaccine occurs when it is separated from a dose of PPSV23 by at least a year. 
What's going on is a dose of PPSV23 given first generates an immune 
response, it generates a set point for that response, beyond which it's not 
possible to boost the antibody levels any higher. 
 
 The effect is thought to last for at least a year, so ACIP made the 
recommendation that when PPSV23 is administered first in adults, regardless 
of the risk factor present, the dose of PCV13 given second must wait an entire 
year. That’s the first interval you see on this slide then, one year. 
 
 In this group of individuals, a second dose of PPSV23 will follow the dose of 
PCV13. This dose must be spaced eight weeks from the dose of PCV13. It 
also has to be spaced five years from that first dose of PPSV23. Also 
remember that the second dose of the PPSV23 is not recommended for CSF 
leak or cochlear implant. 
 
 Finally like in every scenario, the last dose of PPSV23 is recommended after 
the 65th birthday, and this will be the only dose of any pneumococcal vaccine 
recommended after the 65th birthday. 
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 Now we come to 2014 and our new recommendations, which highlight routine 
use of PCV13 for all adults 65 years of age and over, how does this overlay 
for the previous intervals described. First of all, note that this recommendation 
is for PCV13 vaccine-naïve adults 65 years of age and older. So you wouldn't 
give a dose of PCV13 after the 65th birthday if a dose of PCV13 had been 
administered prior to the 65th birthday. 
 
 Also remember that a dose of PPSV23 still is recommended after the 65th 
birthday for all. Keep in mind that a substantial portion of invasive disease in 
adults 65 years of age and older is caused by non-PCV13 types that are in 
PPSV23. So PCV13 is the vaccine that has demonstrated efficacy against 
pneumonia without invasive disease. So we recommend this vaccine first. 
 
 In a healthy adult, the recommended interval between the first dose of PCV13 
and PPSV23 is 12 months. This is not a biologic rationale for this interval. 
Really it's - note PCV13 is being given first but it's more of a 
programmatically-derived interval. In fact, if PPSV23 cannot be given 12 
months later, it should be given during the next visit after that. 
 
 We do state a minimum interval of eight weeks, however, between these two 
different vaccines, and I've already talked about that eight-week interval 
because of risk of mild local reactions that can occur with the two vaccines. 
 
 So if you have an adult 65 years and older, that is high risk. So note that this is 
the interval that should be interval that should be observed if PCV13 if given 
first. You would then give PPSV23 and it could be at an eight-week interval 
for this high risk adult that is at risk for all serotypes. 
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 So remember, if a healthy adult has already received a dose of PPSV23, these 
intervals and recommendations will change. So now we're looking at an adult 
65 years of age and older and they have a history of a dose of PPSV23 given 
first. If the dose of PPSV23 was given first and given after the 65th birthday -- 
remember this is a healthy adult -- PPSV13 has to wait a year prior to receipt 
of PCV13. If a dose of PPSV23 was given before the 65th birthday, the one-
year rule remains. So you have to give a dose of PCV13 now. 
 
 And because that dose of PPSV23 historically was given prior to the 65th 
birthday, they're going to be recommended for another dose of PPSV23 after 
the 65th birthday, which should follow the programmatic interval. This is a 
healthy adult of 12 months, as well as making sure you have five-year interval 
from the prior dose of PPSV23. 
 
 If the adult 65 years old or older previously received a dose of PPSV23 after 
the 65th birthday and this is a high risk adult, you still - we still recommend a 
one-year interval between that dose of PPSV23 and PCV13. So if you have 
control and no vaccine has been given yet, give PCV13 first. When PPSV23 is 
given first, this is bad for expeditious vaccination but sometimes it happens. 
So you wait one year, given PCV13. 
 
 And then in the bottom row, this is the case where PPSV23 was given first but 
before the 65th birthday. Same one-year rule applies for PCV13, and then of 
course now that we're older than 65, you give the second dose of PPSV23. 
Because this adult is high risk, it can follow the dose of PCV13 by eight 
weeks. 
 
 Moving onto to contraindications and precautions. And thankfully, these 
recommendations are somewhat straightforward. The only contraindication 
for both of these vaccines is a severe allergic reaction to a vaccine component 
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or following a prior dose of vaccine. And the only precaution is a moderate or 
severe acute illness. 
 
 I'll take some time to talk about adverse reactions that occur with these 
vaccines. Local reactions occur in 30 to 50% of doses of PPSV23. With 
PPSV23 the rate of fever and myalgia is less than 1%, and severe adverse 
reactions are rare. 
 
 For PCV, local reactions are similar to PPSV23. As you can see, 5 to 49%. 
The rate of fever is higher. And febrile seizures have been observed to occur 
with PCV vaccines. While they're rare, they occur in 1 to 14 out of 100,000 
doses, with a slightly higher rate when other vaccines are administered 
concomitant, particularly influenza vaccine. If both vaccines are administered 
simultaneously, the rate of febrile seizures rises to 4 to 45 out of 100,000 
does. 
 
 Severe local adverse local reactions occur in 8% of doses of PCV vaccine. 
The grading of “severe” included tenderness that affects limb movement. 
That's an interesting categorization of that, but that's what they used when 
they came up with this 8% number. 
 
 The rate of febrile seizures with PCV13 and in concomitant influenza vaccine 
was first identified in 2010, 2011 when the vaccine safety data link program 
and Immunization Safety Office looked at 200,000 children six months 
through four years of age and determined various rates of febrile seizures 
above baseline for these vaccines, individually and in combination. 
 
 The rate of febrile seizures with simultaneous PCV13 and inactivated 
influenza vaccine was 2.5 times higher than PCV13 alone, and 2.4 times 
higher than IIV alone. What does this mean? It means that if, you know, we 
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lived in a world where only one of these two vaccines were recommended, it 
would be preferable to choose one and only one; however, we don't live in 
that world. The risk of the disease exists for both influenza and pneumococcal 
- invasive pneumococcal vaccines. 
 
 Furthermore, febrile seizures are benign and the risk is especially high of 
diseases high for infants for both of these diseases. So in spite of the increased 
risk for febrile seizures, ACIP made no change to the general recommendation 
that these two vaccines can and should be administered simultaneously if both 
vaccines are recommended. 
 
 Severe pneumococcal disease occurs in adults as well as children, as I've 
mentioned repeatedly and are - we have healthy people, 2020 goals, to achieve 
coverage of this vaccine in adults. And we're talking the polysaccharide 
vaccine. We have a recommendation for 90% coverage for persons 65 years 
of age and older. We have a ways to go. 
 
 The 2005 behavioral risk factor surveillance system, a population-based 
random digit dial telephone survey of the non-institutionalized US population, 
estimates that 64% of persons 65 years of age and older were ever vaccinated. 
We have some follow-up data as well from 2012. The National Health 
Interview Survey, which is a household visit survey, estimated 60% coverage 
in this age group, so, you know, those low numbers, 64, 60. We want to get up 
to 90%. And it's even - coverage is much lower, around 20%, among persons 
18 through 64 years of age with a chronic illness. 
 
 And this is because of missed opportunities. We think one of the most 
important missed opportunities to be aware of with this vaccine is mild illness. 
Sixty-five percent of patients with severe pneumococcal disease had been 
hospitalized within the preceding three to five years, yet few had received the 
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vaccine. They should have been vaccinated when no longer moderately or 
severely acutely ill, whether during the hospitalization or at discharge, or 
shortly thereafter. 
 
 There are a number of web pages listed on this slide, job aid to assist in the 
complicated, if you haven't already figured out, risk factor-based decision 
making involved with these two vaccines. 
 
 I would now like to conclude and turn the mic back over to Dr. (Strikas). 
 
(Raymond Strikas): Thank you very much, Dr. (Kroger). To get in queue to ask your questions 
about today's program, please dial star 1 now and we'll have our operator line 
up the questions for queue. While the operator is doing that, let me give you 
some information that the recast of this program and the slides that'll be 
available at www.cdc.gov/vaccines/ed/ciinc for current issues and 
immunization net conference. And they'll be available next week. That is the 
week of August 31 of this year. 
 
 Continuing education to get CE credit, as I said earlier, I'll repeat the website. 
Http://www.2a.cdc.gov/tceonline. The course number for today's program is E 
as in Edward, C as in cat, 2064-082615. Please note the date-specific 
extension when completing the CE requirements for today's program. The 
verification code, which you need to access the CE information, is pneumo26, 
P-N-E-U-M-O 26. I'll repeat that code later. CE credit expires in about one 
month, September 28, 2015. 
 
 And so, operator, do we have any questions in the queue? 
 
Coordinator: We do. Our first question comes from (). Ma'am, your line is open. 
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XXXX: Oh hello. Thanks so much for this great presentation. I just wondered about 
the febrile seizure. You said with pneumo13 and inactivated influenza 
vaccine, there was a 2.4 times increase in febrile seizures than in - than 
receiving it alone. I wondered if that was the same type of - is it observed with 
the live attenuated influenza vaccine also? 
 
(Andrew Kroger): Great question. They didn't - I don’t think it's been looked at as closely. I 
mean, this first came out of observations from a vaccine not even used in the 
United States, a vaccine used in Australia, that febrile seizures could occur 
with administration of influenza vaccines given to young children, and that 
prompted our vaccine safety data link to look at the vaccines used in this 
country. 
 
 They focused mainly on the inactivated product, because that is the one 
administered to persons younger than two years of age. So I don't think a lot 
has been looked at with respect to the live vaccine and febrile seizures given 
concomitantly with pneumococcal conjugate vaccine. So I don't - I certainly 
don't have any detailed data on that combination of the two vaccines. 
 
 This is an ongoing topic of interest, and, you know, these vaccines, you know, 
do cause fever and there's a lot that's being learned about kind of the risk of 
febrile seizures in persons that have - whether they have fevers or not, whether 
it's an intrinsic characteristic of a patient to have a tendency for febrile 
seizures or whether there isn't some kind of additive effect of these vaccines. 
 
 But I can't answer specifically for the live vaccine. All I can say is that there is 
a lot of interest about fever alone in general with a lot of different vaccines. I 
can tell you that live vaccines do tend to cause fevers more often than 
inactivated vaccines. So it's a very good question, but I don't have specific 
data on that. 
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XXXX: And I just wondered do you recommend that the parents be advised of the 
possibility of that increased risk of febrile seizure and give them the 
opportunity to have the vaccine separated? 
 
(Andrew Kroger): We - it's an excellent question, and we actually have information on our VIS 
to discuss this situation with the provider. And it's on the influenza VIS. And 
a bit about the history of that. We know that febrile seizures occur more 
commonly in persons that have already had a febrile seizure. So that for a 
child that has a first febrile seizure, whatever the cause of that first febrile 
seizure, we wanted to make sure this discussion occurred with the provider 
because there are things that can be done. 
 
 We don't want the vaccines separated. That could cause, two fevers a month 
apart, which could be just has high risk of febrile seizure, we don't know. We 
haven't looked at that kind of control data at all for people that actually had 
the two doses separated. But we did want the discussion with the provider to 
occur because of this risk of a repeat febrile seizure occurring, and there are 
other things such as use of antipyretics. 
 
 You know, antipyretics, Tylenol, ibuprofen, are medications to reduce fever 
once fever starts. We don't really like -- they're available for pain as well -- 
but we don't really like them to be used before a fever occurs, although, you 
know, in the circumstance where someone has a history of febrile seizures 
they are faced with having both these vaccines simultaneously. We know that 
the risk of febrile seizures is higher if they're given simultaneously. It makes 
sense to have that discussion with the doctor because of the existence of these 
medicines. So - to reduce fever. 
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 So that's kind of the reason. That's the discussion that we want to have 
happen, but I'll just - the ACIP does not recommend the separation of the two 
vaccines. 
 
XXXX: I really don't understand that because for pneumococcal13, there - that 
increased risk of febrile seizure is not associated with that just given by itself, 
is it? 
 
(Andrew Kroger): You know, we're still looking at this. It doesn't look like it based on - 
although, you know, we're still doing studies on this. There has been some 
follow-up work that's been done on combinations of other vaccines such as 
DTaP vaccine. And there was - it did kind of reveal that there's not much 
going on with PCV13 given by itself. 
 
 But just to repeat, these vaccines do have no windows of administration when 
they have to be given. Someone may be of an age where they're recommended 
for pneumococcal conjugate vaccine during flu season. We know that these 
diseases themselves can cause fevers which can lead to febrile seizures, and 
the vaccine would prevent the disease presumably. And for influenza it's a 
very common disease that's, you know, that very possibly could occur if 
someone's not vaccinated. 
 
 And so no, it does make sense to make sure we prevent the diseases, which 
can cause, you know, the fever just as well as the vaccines can. And we're 
talking about, again, a condition that it extremely scary for parents. Providers 
have a different outlook on febrile seizures. They're benign, they're self-
limited, they're very different from afebrile seizures, and they're quite 
common. So that's the reason why ACIP made a decision not to separate the 
two vaccines. 
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XXXX: Thank you. 
 
(Ramond Strikas): Thank you very much. Operator, do we have another question? 
 
Coordinator: We do. Our next question comes from (). Ma'am, your line is open. 
 
(XXXXX): Yes. In the 2014 MMWR there was a recommendation of giving PCV13 to 65 
and above. The initial interval between the 13 and the 23 was six to 12 
months, with a minimum of 18 - I'm sorry, minimum of eight weeks between 
the 13 and the 23. But with this last ACIP meeting, it was just 12 months for 
13 to 23. And then Medicare of course will not pay - they'll pay for both 
vaccines but only if they're separated by 12 months. 
 
 And you had stressed that high risk people would benefit from having the 13 
followed in eight weeks by the 23 valent. We are working on algorithms to try 
to educate our - the people in our state. And so which in the printed MMWR 
that's going to come out through working with (unintelligible) what is the 
balance between the two recommendations? 
 
(Andrew Kroger): I think you're right that the balance is leaning towards - I mean I think, you 
know, ACIP has discussed this at the last meeting. There's been a lot of back 
and forth on this. The pink book has actually undergone some changes on this 
basis on what that interval should be for high risk. You know, the high risk 
interval between 19 and 64 I believe has been published as eight weeks. 
 
 And so it was a question of why would we rule out the 65 years olds for that 
same interval. And I think we are moving that way, and yes the 
recommendations are coming out in early September. So that's my prediction. 
 
XXXX: Wonderful. We won't finish our algorithms before then. Thank you. 
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(Andrew Kroger): Thank you. Please wait. Thank you. 
 
(Raymond Strikas): Thank you. Do we have an additional question? 
 
Coordinator: We do have final question from Dr. (). Ma'am your line is open. Your line is 
open. 
 
(Raymond Strikas): Operator, is there a question? 
 
Coordinator: I'm not sure. Dr. () did star 1. She recorded her name, but she's not speaking 
now. 
 
(Raymond Strikas): Do we have another question? 
 
Coordinator: No, there are no additional questions. 
 
(Raymond Strikas): Well let me ask Dr. (Kroger) one or two questions. We've got a few 
minutes left in our period here. Dr. (Kroger), a question we receive not 
infrequently is if someone reports having received a dose of pneumococcal 
vaccine but there's no documentation of that vaccination or which vaccine 
they received, can it count? 
 
(Andrew Kroger): Yes, for the pneumococcal polysaccharide vaccine. We've had a published 
recommendation on self-report for that vaccine, but not the pneumococcal 
conjugate vaccine. We do also -- as an aside -- we have a self-report 
allowance also for influenza vaccine. 
 
 For the pneumococcal polysaccharide vaccine, the reason why we allow self-
report, it has its origins in concerns that frequent doses of PPSV23 can cause 
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mild local reactions and, you know, that frequent is a concern when it's, you 
know, within a five-year interval because of the risk of local reactions, and 
five years is quite a long time. 
 
 So hence the reason why, you know, we want to make sure that we limit 
repeat doses of this vaccine, which really caused us to have a low threshold 
for allowing self-report for pneumococcal polysaccharide vaccine. It might 
cause a low threshold for withholding the vaccine on a too-frequent basis. We 
want to make sure that no more than five years between doses of 
pneumococcal polysaccharide vaccine. 
 
(Raymond Strikas): Okay thank you very much. Operator, do we have any questions? 
 
Coordinator: No, currently we do not have any questions. 
 
(Raymond Strikas): Okay. Well I have more here that we've gotten fairly often. Dr. (Kroger), 
can you tell us why you demonstrated that pneumococcal disease risk 
increases substantially for older person, particularly past the 65th birthday, 
why then is only one dose of both the conjugate and particularly the 
polysaccharide vaccine recommended on or after the 65th birthday? 
 
(Andrew Kroger): Well so data suggests that the immune response or the boosting effect for 
subsequent doses is very low, especially after the 65th birthday. There's no 
really any immune yield from additional doses. ACIP also doesn’t recommend 
routine revaccination because of insufficient data regarding the clinical 
benefit, particularly the degree and duration of protection and safety. So that 
follows. But nevertheless, ACIP is going to reevaluate this recommendation in 
the near future. 
 
(Raymond Strikas): Okay thank you. Operator, any questions? 
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Coordinator: Currently there are still no more questions in queue. 
 
(Raymond Strikas): All right. Well we've got another couple that we might be able to fit in. Dr. 
(Kroger), if an adult has already received the conjugate, pneumococcal 
conjugate vaccine and the pneumococcal polysaccharide vaccine 
simultaneously, and I guess this could happen to a child as well, but if they're 
administered simultaneously, that's not recommended, so which should be 
repeated? 
 
(Andrew Kroger): So yes if an adult received PCV13 and PPSV23 simultaneously, neither 
vaccine should be repeated. You know, in this circumstance of course, as you 
mentioned, it should not have been done, and because it was done the PCV13, 
the immune response to that one is no longer as optimal as we would have 
liked it. 
 
 But there's not really any added value in repeating doses of vaccine, especially 
immediately. And likewise, repeating doses of PPSV23 we've talked about 
how there's no boosting effect. It's really not effective at all. So no value there 
either. So it's an interesting situation and very new and very contrary to much 
of what we've recommended in the past with respect to vaccination that, you 
know, we're going - well you can use the term invalid to describe those doses 
but we're not recommending repeating either of them. 
 
(Raymond Strikas): Okay. Thank you. Operator, any questions waiting for us? 
 
Coordinator: No sir, there's still no questions. 
 
(Raymond Strikas): Okay well we'll do one more and I think then we'll wrap up. Dr. (Kroger), 
could you state why the risk factor of invasive pneumococcal disease is so 
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specifically stated as cigarette smoking? Does that apply to other tobacco 
products? 
 
(Andrew Kroger): So we've been asked this a lot about cigars, pipes, and we are - we tailored our 
response to the data that we had, which was limited to cigarettes, and so that's 
how we answer that question is that it's a risk factor limited to cigarette 
smoking. It's interesting but we live in a data-driven world. That's the data that 
we had. 
 
 I want to - as a follow up upon that, the more important point with this 
situation is it's a risk that was identified in persons 19 years old and older. So 
we actually used the data that we have and we limit the recommendation to 19 
year old and older. And we go back and forth on this from time to time, and 
it's a complicated issue how we're going to use, you know, the evidence base 
to make our recommendations when there's not really much of a rationale for 
excluding persons younger than 19 years of age. But that's kind of the 
recommendations as they are written. 
 
 You know, the cigarette smoking, it's - interestingly it's linked to the outcome-
invasive pneumococcal disease. So it is really a nuanced data-driven finding. 
It's not a simple issue of, you know, what you might think - destruction of the 
respiratory system and any effect that would have on the risk of pneumonia. 
We're talking about invasive pneumococcal disease. Perhaps it's linked to the 
outcome of invasive disease, and so that's why we have that recommendation 
that's specific to cigarette smoking in persons 19 years of age and older. 
 
(Raymond Strikas): Okay well thank you very much. Then I'll thank you for the presentation 
and addressing the questions. So can we go to the last slide set please? 
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 So I'll remind you again about the continuing education information to make 
sure you have it. You've seen the website several times for CE credit. I won't 
read it again. It's there on your slide set. It's also on our website for these 
Internet conferences. 
 
 The course number again is E as in Edward, C as in cat, 2064-082615. Please 
note again the data-specific extension to the course number when completing 
the CE requirements. The verification code again is pneumo26, P-N-E-U-M-O 
26, and CE credit expires on September 28, 2015 in about one month. 
 
 For help with the online CE system, you may call us between 8 and 4 Eastern 
Time at 1-800-41-TRAIN, or you can e-mail us at ce@cdc.gov. If you have 
questions that you didn't get a chance to answer or prefer to ask it by e-mail, 
please e-mail us at nipinfo@cdc.gov and please refer to today's program so we 
know how to direct your questions. 
 
 You may call us about your immunization questions at 1-800-CDC-INFO 8 
am to 8 pm Eastern Time, and one of our staff will answer the question or 
refer it to a specialist as necessary. And that phone line is available 8 am to 8 
pm Eastern Time Monday through Friday. 
 
 Additional resources for this program are available in the pink book, The 
Epidemiology and Prevention of Vaccine-Preventable Diseases, the 13th 
edition, published this year at cdc.govvaccines/pubs/pinkbook. The CDC 
vaccines homepage is cdc.gov/vaccines. And CDC immunization resources 
for you and your patients are listed there on the vaccines website, and you can 
also tweet us using Twitter at cdcizlearn, L-E-A-R-N, if you wish to. 
 
 Thank you very much for joining today's program. We'll repeat - not repeat 
the program, but the recast will be available next week and we'll have a new 
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program for you a week from today at noon Eastern Time. Thank you very 
much and goodbye from Atlanta. 
 
Coordinator: This concludes your conference call and you may disconnect. Once again, 
your conference call has ended and you may disconnect. Thank you for 
joining. 
 
 
END 
